B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study

The humoral response to SARS-COV-2 vaccines in MS patients: A case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type

“…Similar to the study by Conte, we did not find an association between S1P modulators and the humoral vaccine response ( Conte, 2022 ). However, we only included four patients on S1P modulators so we cannot draw any strong conclusions in regards to this medication class.…”

Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis

“…Several lines of evidence indicate anti-CD20 therapy commonly used to treat MS as well as other autoimmune disease and hematologic malignancies, may lead to blunted humoral response after vaccination against SARS-CoV-2. 10 , 11 , 12 Attenuated post-vaccination seroconversion of pwMS treated with sphingosine-1-phosphate receptor modulator (S1PRM), such as fingolimod, has also been observed, 13 , 14 while there are inconsistent results. 15 Despite accumulating data on immunosuppressive DMTs, the effects of the broad spectrum of MS treatment regimens on the humoral and cellular immune responses after COVID-19 vaccination have not yet been fully understood.…”

Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications

“…Nevertheless, immune compromised patients are less able to mount an appropriate immune response to vaccination, leaving this vulnerable population at risk for severe infections (Bar-Or et al, 2020; van Assen et al, 2010;Iannetta et al, 2021;Smets et al, 2021;Tallantyre et al, 2022;Georgieva et al, 2021). B-cell depleting medications, commonly used to treat patients with multiple sclerosis (MS) as well as other autoimmune diseases, may put individuals at greater risk for severe COVID-19 infection, as well as impair their humoral response to vaccination (Bar-Or et al, 2020;Waldman et al, 2021;Conte, 2021). More information about how DMT impact vaccination responses is needed to develop effective management strategies for MS patients (Baker et al, 2020).…”